<DOC>
	<DOCNO>NCT00094445</DOCNO>
	<brief_summary>The goal clinical research study learn treatment curcumin help shrink slow growth pancreatic cancer . The effect curcumin way pancreatic cancer cell function safety treatment curcumin also study .</brief_summary>
	<brief_title>Trial Curcumin Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Curcumin , yellow substance extract plant Curcuma longa , commonly use food additive . It natural anti-inflammatory compound show anti-tumor activity laboratory . During study , receive much high dos curcumin obtain diet . During study , receive curcumin mouth every day . You require take 16 pill per day morning . Every 8-week period take curcumin consider `` course '' treatment . The number course receive depend respond treatment . You continue treatment long disease get bad . If disease get bad experience intolerable side effect , take study doctor discus treatment option . You give questionnaire complete begin study week therapy help medical staff understand different symptom disease affect . This questionnaire , take 5 minute complete , do telephone help one study staff visit . At end course treatment ( every 8 week ) , physical exam tumor re-evaluated use CT scan and/or blood ( 2 tablespoon ) test . This investigational study . Curcumin commercially available substance , commonly use food additive . Up 50 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>1 . The patient pathologically confirm adenocarcinoma pancreas amenable curative surgical resection ( include locally advanced , metastatic , recurrent disease ) . Histology must confirm pathology department investigational center . 2 . The patient Karnofsky Performance Status great equal 60 study entry . 3 . The patient give informed consent . 4 . The patient least 18 year age . 5 . The patient adequate hematologic function define absolute neutrophil count great equal 1,500/mm3 , platelet count great equal 100,000/mm3 . 6 . The patient adequate hepatic function define total bilirubin less equal 2.0 X ULN , alkaline phosphatase , AST and/or ALT le equal 5 X ULN , creatinine le equal 2.0 mg/dL . 7 . The patient measurable disease . 8 . The patient agree use effective contraception procreative potential exists . 1 . The patient history treat active brain metastasis , carcinomatous meningitis , uncontrolled seizure disorder , active neurological disease . 2 . The patient receive prior radiation . Patients measurable disease outside radiation port document disease progression previously irradiate measurable disease eligible . Patient must great equal four week posttherapy recover toxicity . 3 . The patient unstable medical condition accord investigator , include uncontrolled diabetes mellitus hypertension ; active infection require systemic antibiotic , antiviral , antifungal , unstable CHF , uncontrolled arrythmias , unstable coagulation disorder . 4 . The patient pregnant ( confirm serum BetaHCG ) breast feeding . 5 . The patient receive investigational agent ( ) within four week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Adenocarcinoma pancreas</keyword>
	<keyword>Alternative therapy</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic Neoplasm</keyword>
	<keyword>Cancer pancreas</keyword>
</DOC>